Oppenheimer analyst Hartaj Singh lowered the firm’s price target on Spruce Biosciences to $7 from $8 and keeps an Outperform rating on the shares after the company reported Q2 results. With early validation in PCOS and upcoming late-stage readouts in CAH, the firm updates its model and valuation, and remains bullish.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SPRB: